- Home
- VRTX vs SNOW Comparison
VRTX vs SNOW Comparison
Compare VRTX & SNOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRTX | SNOW |
|---|---|---|
| Founded | 1989 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Computer Software: Prepackaged Software |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.6B | 111.9B |
| IPO Year | 2006 | 2020 |
Fundamental Metrics
Financial Performance| Metric | VRTX | SNOW |
|---|---|---|
| Price | $553.38 | $291.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 32 | 52 |
| Target Price | ★ $571.46 | $426.50 |
| AVG Volume (30 Days) | 1.3M | ★ 4.1M |
| Earning Date | 11-02-2026 | 12-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 836.54 | N/A |
| EPS | ★ 8.33 | N/A |
| Revenue | $2,488,652,000.00 | ★ $4,683,946,000.00 |
| Revenue This Year | $10.66 | $34.92 |
| Revenue Next Year | $9.94 | $28.64 |
| P/E Ratio | $67.08 | ★ N/A |
| Revenue Growth | ★ 46.20 | 29.16 |
| 52 Week Low | $403.16 | $118.30 |
| 52 Week High | $563.80 | $384.56 |
Technical Indicators
Market Signals| Indicator | VRTX | SNOW |
|---|---|---|
| Relative Strength Index (RSI) | 64.51 | 35.48 |
| Support Level | $461.04 | $253.30 |
| Resistance Level | $557.97 | $345.28 |
| Average True Range (ATR) | 14.71 | 16.59 |
| MACD | 5.34 | -3.34 |
| Stochastic Oscillator | 81.83 | 0.00 |
Price Performance
Historical ComparisonAbout VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).
About SNOW Snowflake Inc.
Founded in 2012, Snowflake is a fully managed platform that consolidates data hosted on different public clouds for centralized analytics and governance. Snowflake's cloud-native architecture allows users to independently scale the compute and storage layers, providing customers with optimized performance at lower costs. The company's data lake and data warehouse products support a variety of use cases, including business analytics, data engineering, and artificial intelligence. Snowflake is widely used by Fortune 2000 companies in financial services, media, and retail sectors.